hapalindole U: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
hapalindole U : A hapalindole that is hapalindole H in which the octahydronaphthalene ring junction carbons both have S configuration instead of R. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 16069589 |
| CHEMBL ID | 2071364 |
| CHEBI ID | 141613 |
| MeSH ID | M0508465 |
| Synonym |
|---|
| hapalindole u |
| 106928-30-7 |
| CHEBI:141613 |
| (6as,9r,10r,10as)-10-isocyano-6,6,9-trimethyl-9-vinyl-2,6,6a,7,8,9,10,10a-octahydronaphtho[1,2,3-cd]indole |
| CHEMBL2071364 |
| 8p6 , |
| C21973 |
| DTXSID601316244 |
| (-)-hapalindole u |
| [6as,(+)]-9alpha-ethenyl-2,6,6aalpha,7,8,9,10,10abeta-octahydro-10alpha-isocyano-6,6,9-trimethylnaphtho[1,2,3-cd]in |
| (2s,3r,4r,7s)-4-ethenyl-3-isocyano-4,8,8-trimethyl-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),9(16),10,12-tetraene |
| Class | Description |
|---|---|
| isocyanide | The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)). |
| organic heterotetracyclic compound | |
| hapalindole | Any member of large group of hapalindole-type alkaloids that are bioactive metabolites of the Subsection V (formerly order Stigonematales)in the phylum Cyanobacteria which have either a tetracyclic structure based on 10-isocyano-6,6,9-trimethyl-9-vinyl-2,6,6a,7,8,9,10,10a-octahydronaphtho[1,2,3-cd]indole, or a tricyclic structure resulting from the cleavage of the bond linking the indole ring to the dimethyl-substituted carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID677136 | Cytotoxicity against human SF268 cells incubated for 3 days by SRB assay | 2012 | Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17 | Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. |
| AID677133 | Cytotoxicity against human HT-29 cells by CellTiter 96 Aqueous One solution cell proliferation assay | 2012 | Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17 | Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. |
| AID677135 | Cytotoxicity against human NCI-H460 cells incubated for 3 days by SRB assay | 2012 | Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17 | Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. |
| AID677137 | Cytotoxicity against human IMR90 cells incubated for 3 days by SRB assay | 2012 | Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17 | Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. |
| AID677134 | Cytotoxicity against human MCF7 cells incubated for 3 days by SRB assay | 2012 | Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17 | Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||